Watson to establish global r&d centre in New Jersey


Will invest US$5.4m in outfitting the new facility

Global pharmaceutical firm Watson Pharmaceuticals is to establish a Global R&D Technology Center in North Brunswick, New Jersey.

The company has signed a lease for a 32,000ft2 of space and plans to retrofit approximately 19,000ft2 for product development and analytical laboratories. The remaining 13,000ft2 will accommodate future expansion.

Watson Pharmaceuticals intends to invest approximately US$4.5m in outfitting the new facility.

The facility, which should be completed in the spring, will employ approximately 50 scientists, chemists, engineers and support staff.

Watson’s president and ceo Paul Bisaro said the location of the new Global R&D Technology Center will enable Watson ‘to leverage our proximity to such educational centres of excellence as Rutgers University’.

The centre will become Watson’s state-of-the-art facility for developing generic pharmaceutical products, in particular for inhalation technology and respiratory products, with the ability to conduct formulation development and analytical testing.

In addition, it will focus on process analytical technology, packaging development, pharmaceutical technology, inhalation technology and new technology evaluation.